14 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
have trouble attracting new collaborators, we may be subject to breach of contract claims by our collaborators, and we may suffer reputational and other … or all of these issues could result in reputational damage or subject us to third‑party lawsuits or other action or liability, which could adversely
10-Q
2023 Q3
NMRA
Neumora Therapeutics Inc.
1 Nov 23
Quarterly report
4:05pm
and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
suffer reputational and other harm as a result. Federal, state and foreign laws and regulations may also expose us to enforcement actions … security efforts fail. Any or all of these issues could
result in reputational damage or subject us to third-party lawsuits or other action
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
collaborators, and we may suffer reputational and other harm as a result. Federal, state and foreign laws and regulations may also expose us to enforcement … information technology security efforts fail. Any or all of these issues could
result in reputational damage or subject us to third-party lawsuits or other
S-1
9xmhkir69x dw5x63pw
25 Aug 23
IPO registration
5:03pm
DRS/A
aw6lellx8aax
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
cgs3d0zw9 3nu
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
5u9d6eawby89jfg
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
zze4q
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
xysg89m2 69utp0r
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
ke2ffuj
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
k213uy gctdxf8s80
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
7cqow4d le52
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next